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OBJECTIVES: To investigate cognitive impairment in
older, ethnically diverse individuals with a broad range of
kidney function, to evaluate a spectrum of cognitive do-
mains, and to determine whether the relationship between
chronic kidney disease (CKD) and cognitive function is in-
dependent of demographic and clinical factors.
DESIGN: Cross-sectional.
SETTING: Chronic Renal Insufficiency Cohort Study.
PARTICIPANTS: Eight hundred twenty-five adults aged
55 and older with CKD.
MEASUREMENTS: Estimated glomerular filtration rate
(eGFR, mL/min per 1.73 m2) was estimated using the four-
variable Modification of Diet in Renal Disease equation.
Cognitive scores on six cognitive tests were compared
across eGFR strata using linear regression; multivariable
logistic regression was used to examine level of CKD and
clinically significant cognitive impairment (score 1 stan-
dard deviations from the mean).
RESULTS: Mean age of the participants was 64.9, 50.4%
were male, and 44.5% were black. After multivariable ad-
justment, participants with lower eGFR had lower cogni-
tive scores on most cognitive domains (Po.05). In addition,
participants with advanced CKD (eGFRo30) were more
likely to have clinically significant cognitive impairment on
global cognition (adjusted odds ratio (AOR) 2.0, 95%
CI 5 1.1–3.9), naming (AOR 5 1.9, 95% CI 5 1.0–3.3),
attention (AOR 5 2.4, 95% CI 5 1.3–4.5), executive func-
tion (AOR 5 2.5, 95% CI 5 1.9–4.4), and delayed memory
(AOR 5 1.5, 95% CI 5 0.9–2.6) but not on category flu-
ency (AOR 5 1.1, 95% CI 5 0.6–2.0) than those with mild
to moderate CKD (eGFR 45–59).
CONCLUSION: In older adults with CKD, lower level of
kidney function was associated with lower cognitive func-
tion on most domains. These results suggest that older pa-
tients with advanced CKD should be screened for cognitive
impairment. J Am Geriatr Soc 58:338–345, 2010.
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The prevalence of chronic kidney disease (CKD) increaseswith advancing age. Similarly, cognitive impairment
is more common in older adults. Both conditions are asso-
ciated with greater healthcare use and poorer quality of life
and are of increasing public health significance.1,2 Whether
CKD is associated with accelerated cognitive aging has
not been rigorously addressed. There are several potential
mechanisms, including cerebrovascular disease,3–5 metabolic
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dysregulation,6 and direct effects of kidney disease7–9 that
may link CKD with impaired cognitive function.
The few studies that have investigated the association
between CKD before kidney failure and cognitive outcomes
suggest that older adults with very low levels of kidney
function have worse cognitive function than those without
CKD,10–14 but little is known about the specific cognitive
domains affected in CKD, because most of the prior
research studies have used global cognitive screening mea-
sures rather than tests of specific domains. In addition, they
had limited representation of minority subjects and a
limited range of kidney function.
The Chronic Renal Insufficiency Cohort (CRIC) Study,
a prospective observational cohort study, was established to
examine the risk factors and mechanisms of progression of
CKD and cardiovascular disease (CVD). The CRIC Cog-
nitive (CRIC COG) Study, an ancillary study to CRIC,
provided the opportunity to investigate cognitive impair-
ment in older, ethnically diverse individuals with a broad
range of kidney function, to evaluate a spectrum of cogni-
tive domains, and to determine whether the relationship
between CKD and cognitive function is independent of de-
mographic and clinical factors.
METHODS
Study Design
The CRIC Study is a prospective cohort study designed to
evaluate the risk factors and mechanisms of progression of
CKD and CVD in adults with mild to moderate CKD. A
total of 3,612 participants (47.0% with diabetes mellitus
(DM)) were enrolled at seven clinical centers from May
2003 to March 2007 and are being followed annually until
death or withdrawal of informed consent. The study design
and methods have been published previously.15
The present study of cognitive function, called the
CRIC COG Study, is ancillary to the parent CRIC Study.
Similar to its parent study, the CRIC COG is a prospective
observational cohort study that recruited study participants
from four of the seven clinical CRIC centers located in
Philadelphia, Pennsylvania; Cleveland, Ohio; Oakland,
California; and Chicago, Illinois. Only persons enrolled in
the CRIC Study and who were aged 55 and older were
eligible for the cognitive function study. At their next
scheduled in-clinic visit, eligible participants were enrolled
in the CRIC COG Study and administered a cognitive bat-
tery. This served as the baseline visit for the study but may
not have coincided with the baseline visit for the parent
study. Thus ‘‘baseline’’ in this report is the participants’ first
visit as part of CRIC COG Study.
Institutional review boards at each of the participating
sites and at the University of California at San Francisco
approved the CRIC COG Study, and all participants gave
written informed consent.
Study Population
To be enrolled in the CRIC Study, participants must be aged
21 to 74 and have an estimated glomerular filtration rate
(eGFR) of 20 to 70 mL/min per 1.73 m2 if aged 21 to 44, 20
to 60 mL/min per 1.73 m2 if aged 45 to 64, and 20 to 50 mL/
min per 1.73 m2 if aged 65 to 74. They were not eligible if
they were institutionalized, did not provide informed con-
sent, had previously undergone dialysis for longer than 1
month, were diagnosed with polycystic kidney disease, had
received a prior organ or bone marrow transplant, were
taking immunosuppressive drugs for kidney disease in the
past 6 months, or were currently participating in a clinical
trial or the African American Study of Kidney Disease and
Hypertension, an ongoing cohort study at some of the cen-
ters. Other exclusions included New York Heart Associa-
tion Class III or IV heart failure, cirrhosis, human
immunodeficiency virus infection or acquired immunode-
ficiency syndrome, chemotherapy for cancer within 2 years,
multiple myeloma, or renal cell carcinoma.15 The CRIC
COG Study required that participants be enrolled in the
CRIC Study and be aged 55 and older. This minimum age
requirement was established to increase the likelihood of
observing clinically significant cognitive decline in the sam-
ple. The target sample size was 720, with equal recruitment
from the four clinical centers.
Predictor Variable
The primary predictor of interest was level of kidney func-
tion. eGFR was calculated using the Modification of Diet in
Renal Disease (MDRD) estimating equation.16 Whenever
possible, the eGFR value determined at the CRIC visit
coinciding with the CRIC COG baseline visit was used. In
cases (n 5 8; 0.9%) in which visits did not coincide or when
eGFR was missing, the most recent eGFR value was used
(mean interval of 1.4 years).
Cognitive Function Measures
Six cognitive function tests (with 7 scores) were adminis-
tered in the CRIC COG Study: the Modified Mini-Mental
State Examination (3MS), the Trail Making Test Parts A
and B (Trails A and B), Category (verbal) Fluency, Buschke
Selective Reminding Test (immediate and delayed memory),
and Boston Naming. The 3MS is a brief, general cognitive
battery with components for orientation, concentration,
language, praxis, and immediate and delayed memory, with
scores ranging from 0 to 100, higher scores indicating better
function.17 Trails A and B measure visuospatial scanning,
motor speed, executive function, and attention.18 Trails B is
primarily a test of executive function, and Trails A is pre-
dominantly a test of attention. The scores are based on the
time to complete a particular task, and therefore, lower
scores indicate higher function. Category (verbal) Fluency
measures verbal production, semantic memory, and lan-
guage, with higher scores indicating better performance.19
Category Fluency and Trails B are typically impaired in the
context of subcortical vascular disease.20 The Buschke Se-
lective Reminding Test is a well-established test of verbal
memory, with immediate and delayed components.21 Ver-
bal memory is one of the earliest cognitive domains to be
affected in Alzheimer’s disease (AD) and is a hallmark fea-
ture of all dementias.22 Higher scores indicate higher func-
tion. The Modified Boston Naming test is a 15-item test of
language function that requires the participant to name
objects presented in pictures.19 Language deficits, such as
those found with naming, are a hallmark feature of early
AD. Higher scores indicate higher function.
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Clinically significant impairment was defined as having
a score 1 standard deviation (SD) below the mean or lower,
except for the Trails A and B, in which case impairment was
a score at least 1 SD above the mean.
Covariates
Covariates included additional data collected as part of the
CRIC Study, including sociodemographic characteristics,
relevant medical history (diabetes mellitus, diagnosed hyper-
tension; self-reported at each annual clinic visit if a doctor
told them they had that condition), body mass index (BMI;
measured as weight (kg) divided by the square of height
(m)), and resting blood pressure (systolic and diastolic;
mean of three seated measurements, 30 seconds apart),
each measured or updated annually. The Beck Depression
Inventory (BDI) was collected biannually and moderate
to severe depression was defined as a score greater than 14.23
Statistical Methods
Baseline characteristics were compared across eGFR cate-
gories (60, 45–59, 30–44, and o30 mL/min per 1.73 m2)
using analysis of variance for normally distributed contin-
uous data, Kruskal-Wallis test for nonnormally distributed
continuous data, and chi-square tests for categorical data.
Tests for trend were performed using the Cochran-Armitage
Trend Test on categorical variables and orthogonal poly-
nomial contrasts within the general linear models for con-
tinuous variables. The outcome variables of interest are the
six cognitive function tests, resulting in seven scores. The
primary analysis was a comparison of each score across
category of eGFR level using a linear regression model, so
an association between kidney function and cognitive func-
tion could be tested for. Adjustment was made for the fol-
lowing possible confounding variables based on their
association (Po.10) with CKD and cognitive function:
age, education, sex, BMI, diabetes mellitus, hypertension,
and depression. Additionally, adjustment was made for race
based on prior published studies showing separate associ-
ations between race and CKD9–11 and between race and
cognitive function.24,25
Differences in likelihood of clinically significant cognitive
impairment were further tested for across eGFR strata using
logistic regression models, with adjustment for age, race, ed-
ucation, sex, BMI, diabetes mellitus, hypertension, and de-
pression score. For these analyses, the reference group was the
subgroup of participants with eGFR of 45 to 59 mL/min per
1.73 m2. (The 80 participants with eGFR 60 mL/min per
1.73 m2 were not chosen to be the reference, because they had
demonstrated lower levels of kidney function at the time of
screening several months before and did not seem to appro-
priately represent older adults with eGFR60.) Results are
summarized with odds ratios (ORs) and 95% confidence in-
tervals (CIs). Models were run with and without adjustment
for possible confounders. All analyses were done using SAS
version 9.1 (SAS Institute, Inc., Cary,. NC).
RESULTS
A total of 825 participants were recruited into the CRIC
COG Study (of those who were eligible; 983 were asked to
participate). This cohort had a mean age  SD of 64.9  5.6
and was 50.4% male and 44.5% black. Site enrollment in-
cluded 205 participants from the University of Pennsylvania
center, 223 participants from the Case Western Reserve cen-
ter, 196 from the University of Illinois at Chicago center, and
201 from the Kaiser Permanente of Northern California/Uni-
versity of California San Francisco center. At the time of
cognitive testing, mean eGFR was 41.0  14.3 mL/min per
1.73 m2, with 80 participants having an eGFR of 60 mL/min
per 1.73 m2 or greater (mean 61 mL/min per 1.73 m2), 289
with an eGFR of 45 to 59 mL/min per 1.73 m2 (mean 49 mL/
min per 1.73 m2), 299 with an eGFR of 30 to 44 mL/min per
1.73 m2 (mean 37 mL/min per 1.73 m2), and 157 with an
eGFR of less than 30 (mean 24) mL/min per 1.73 m2). The
characteristics of the CRIC COG participants were compared
across eGFR categories (Table 1). Participants with lower
eGFR tended to be older and have less educational attainment
and greater comorbidity burden, including diabetes mellitus
and hypertension.
In unadjusted analyses, for each of the cognitive tests, a
consistent pattern of worse cognitive scores in participants
with greater CKD severity was observed. For example, for
the 3MS, participants with an eGFR of 60 mL/min per
1.73 m2 or greater had a mean score of 95.2  5.0, those
with an eGFR of 45 to 59 mL/min per 1.73 m2 had a score of
94.0  7.6, those with an eGFR of 30 to 44 mL/min per
1.73 m2 had a score of 92.1  7.1, and those with an eGFR
less than 30 mL/min per 1.73 m2 had a score of 91.4  7.8
(Po.001 for trend). For the Trails B test, mean scores were
115.7  70.3, 126.1  70.1, 150.9  83.0, and 163.9 
85.1, respectively (Po.001 for trend). A similar pattern
emerged for the other four cognitive tests (5 subscores).
Multivariable adjustment for age, sex, race, education, BMI,
diabetes mellitus, hypertension, and depression did not alter
the findings, with the exception of the Category Fluency and
Buschke tests (Table 2).
The association between severity of CKD and clinically
significant cognitive impairment, defined as a score 1 SD or
more more severe from the mean, was next determined
(Table 3). Participants with more-severe CKD had higher
prevalence of cognitive impairment on global cognition
(21.7% for eGFRo30 mL/min per 1.73 m2, 14.1% for
eGFR 30–44 mL/min per 1.73 m2, 9.7% for eGFR 45–
59 mL/min per 1.73 m2, 5.0% for eGFR 60 mL/min per
1.73 m2, Po.001 for trend), attention (20.4%, 16.5%,
8.7%, 3.8%, respectively, Po.001), executive function
(28.0%, 23.2%, 12.2%, 11.3%, respectively, Po.001),
naming (23.6%, 20.1%, 12.5%, 7.5%, respectively,
Po.001), category fluency (16.6%, 15.2%, 12.5%,
5.0%, respectively, P 5.02), and delayed memory
(19.1%, 17.4%, 13.3%, 5.0%, respectively, P 5.003). Al-
though this pattern was also evident for the test of imme-
diate memory (22.3%, 22.1%, 17.0%, 18.8%, respectively,
P 5.16), the differences were not statistically significant.
After multivariable adjustment for age, sex, race, educa-
tion, hypertension, depression, BMI, and diabetes mellitus,
participants with more-severe CKD continued to demon-
strate greater likelihood of cognitive impairment on most
tests (Figure 1). Participants with advanced CKD (eG-
FRo30) were more likely to have cognitive impairment on
tests of global cognition (adjusted odds ratio (AOR) 5 2.0,
95% CI 5 1.1–3.9), naming (AOR 5 1.9, 95% CI 5 1.0–
3.3), attention (AOR 5 2.4, 95% CI 5 1.3–4.5), executive
function (AOR 5 2.5, 95% CI 5 1.9–4.4) and delayed
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memory (AOR 5 1.5, 95% CI 5 0.9–2.6) but not on cate-
gory fluency (AOR 5 1.1, 95% CI 5 0.6– 2.0) or immediate
memory (AOR 5 1.2, 95% CI 5 0.7–2.1) than those with
mild or moderate CKD (eGFR 45–59).
In subgroup analyses defined a priori according to a di-
agnosis of diabetes mellitus, race (black vs white) and sex,
consistent interactions for these strata (P4.10 for all) and the
association between level of eGFR and cognitive function
were not observed. The cohort was also stratified according
to age (55–64, 65–74, and 75), and it was found that the
prevalence of global cognitive impairment (defined according
to the 3MS) was 9.1%, 18.4%, and 13.3%, respectively, but
there was no interaction according to age on the association
between CKD severity and cognitive function.
DISCUSSION
In the CRIC COG Study, it was found that baseline cog-
nitive function measured across multiple domains was
worse in participants with more-severe kidney disease, even
after adjustment for several potential confounders, includ-
ing demographic characteristics and relevant comorbidities.
The proportion of participants with clinically meaningful
cognitive impairment was much greater for those with
Table 2. Adjusted Mean Cognitive Function Score According to Baseline Level of Estimated Glomerular Filtration Rate
(eGFR)
Cognitive Test N
eGFR (mL/min per 1.73 m2) Mean (Standard Error)
P-Value60 45–59 30–44 o30
Modified Mini-Mental State Examination (range 0–100) 813 92.8 (0.82) 92.2 (0.61) 91.2 (0.62) 91.0 (0.70) .01
Trail Making Test (range 0–300)
Part A 810 49.3 (4.44) 53.7 (3.30) 62.9 (3.37) 68.0 (3.77) o.001
Part B 809 143.3 (8.58) 148.1 (6.38) 161.2 (6.50) 170.0 (7.28) o.001
Boston Naming (range 0–15) 811 13.6 (0.18) 13.5 (0.11) 13.3 (0.11) 13.2 (0.13) .02
Category Fluency (range 0–45) 811 17.7 (0.61) 16.4 (0.46) 16.5 (0.46) 16.6 (0.52) .11
Buschke Selective Reminding Test
Immediate Recall (range 0–12) 813 6.4 (0.24) 6.3 (0.18) 6.1 (0.18) 6.1 (0.20) .14
Delayed Recall (range 0–12) 804 7.9 (0.37) 7.4 (0.28) 7.4 (0.28) 7.3 (0.32) .12
Adjusted for age, race, education, sex, diabetes mellitus, hypertension, body mass index, and depression.
Higher scores indicate higher function for all tests except for Trails A and B, on which lower scores are better.
P-value for test of trend.
Table 1. Characteristics of the 825 Participants Enrolled in the Chronic Renal Insufficiency Cohort Cognitive Function
Study
Characteristic
eGFR (mL/min per 1.73 m2)
P-Value60 (n 5 80) 45–59 (n 5 289) 30–44 (n 5 299) o30 (n 5 157)
Age, mean  SD 61.5  3.5 64.8  5.6 65.5  5.7 65.6  5.7 o.001
Male, n (%) 44 (55.0) 162 (56.1) 139 (46.5) 71 (45.2) .05
Race, n (%) .70
White 42 (52.5) 144 (49.8) 145 (48.5) 70 (44.6)
Black 33 (41.3) 120 (41.5) 138 (46.2) 76 (48.4)
Other 5 (6.3) 20 (6.9) 14 (4.7) 11 (7.0)
Hispanic ethnicity 2 (2.5) 11(3.8) 6 (2.0) 3 (1.9) .51
Education high school, n (%) 22 (27.5) 82 (28.4) 124 (41.5) 67 (42.7) o.001
Married or domestic partner, n (%) 50 (62.5) 165 (57.1) 151 (50.5) 83 (52.9) .18
Diabetes mellitus, n (%) 32 (40.0) 125 (43.3) 176 (58.9) 88 (56.1) o.001
Current smoker, n (%) 10 (12.5) 27 (9.3) 40 (13.4) 14 (8.9) .33
Hypertension, n (%) 62 (77.5) 251 (86.9) 289 (96.7) 150 (95.5) o.001
Stroke, n (%) 5 (6.3) 30 (10.4) 37 (12.4) 20 (13.4) .40
Depression, n (%) 13 (16.3) 31 (10.7) 59 (19.7) 21 (13.4) .02
Body mass index, kg/m2, mean  SD 31.0  5.9 31.3  7.8 32.9  7.8 32.1  8.5 .06
Systolic blood pressure, mean  SD 119.3  14.3 126.5  21.2 129.9  24.2 130.9  22.3 o.001
Diastolic blood pressure, mean  SD 68.7  11.8 67.6  12.2 67.1  12.5 65.7  11.5 .28
P-value is for test of differences across levels of estimated glomerular filtration rate (eGFR).
SD 5 standard deviation.
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more-severe CKD as well. This pattern was observed for
most of the cognitive domains, including global cognition,
verbal memory, attention, naming, and executive function,
but not for verbal fluency. Similar findings were observed
for participants with and without diabetes mellitus, men
and women, and blacks and whites.
These findings support and extend the findings ob-
served by several published cross-sectional studies. Of
1,015 postmenopausal women with CVD, for every 10 mL/
min per 1.73 m2 reduction in GFR, there was a 27% in-
crease in likelihood of global cognitive impairment. In more
than 20,000 U.S. adults, lower levels of kidney function
were found to be associated with greater prevalence of
cognitive impairment.13 Level of eGFR was associated with
cognitive impairment on executive function, memory, and
language measures.26 In other studies, subjects with CKD
had significantly poorer performance on tests of executive
function, verbal memory, and global performance.27,28
Similarly, patients with CKD performed significantly worse
on executive and memory measures than controls in a small
clinical sample.14 The few longitudinal studies that have
been conducted on CKD and cognition also support the
current study’s observations. Of more than 3,000 older
adults, those with CKD (defined as an eGFR o60 mL/min
per 1.73 m2) had greater 3MS score decline over 4 years
than those without CKD, although there were few partic-
ipants with severe CKD.10 One of the only studies to in-
vestigate the association between CKD and dementia
reported a high risk of incident dementia in elderly sub-
jects with CKD participating in the Cardiovascular Health
Cognition Study,11 although another longitudinal study did
not find an association between kidney function and global
cognitive impairment or risk in cognitive decline.12 This
may be due to differences in study populations, because that
study cohort comprised older community-dwelling men
primarily without CKD.12
There are several mechanisms that might link
CKD with cognitive impairment. Individuals with CKD
have a greater prevalence of established CVD and cardio-
vascular risk factors, and these same risk factors increase
the risk of developing dementia, including AD and vascular
dementia.3 CKD is also associated with a number of other
factors that also may induce cognitive impairment, includ-
ing anemia, high levels of inflammatory cytokines, oxida-
tive stress, and alterations in lipid and homocysteine
metabolism.29–33
This study is an important step in advancing under-
standing of the important role that kidney function may
play in cognitive aging. Strengths of this study are its re-
cruitment of patients from the ongoing CRIC Study, which
includes a large number of patients with a range of CKD
severity, allowing the association between severity of CKD
and cognitive function to be explored; the administration of
sensitive cognitive tests that evaluate a range of cognitive
domains; and the ability to adjust for differences across
levels of kidney function in important possible confounders
to determine whether the association between CKD and
Table 3. Prevalence and Unadjusted Odds Ratios of Clinically Significant Cognitive Impairment, According to Esti-
mated Glomerular Filtration Rate (eGFR) Group
Cognitive Test
eGFR Rate (mL/min per 1.73 m2) %; Odds Ratio (95% Confidence Interval)
60 45–59 30–44 o30
Modified Mini-Mental State Examination 5.0; 0.5 (0.2–1.4) 9.7; Reference 14.1; 1.5 (0.9–2.5) 21.7; 2.6 (1.5–4.4)
Trail Making Test
Part A 3.8; 0.4 (0.1–1.4) 8.7; Reference 16.5; 2.1 (1.2–3.5) 20.4; 2.7 (1.5–4.7)
Part B 11.3; 0.9 (0.4–2.0) 12.2; Reference 23.2; 2.2 (1.4–3.4) 28.0; 2.8 (1.7–4.6)
Boston Naming 7.5; 0.6 (0.2–1.4) 12.5; Reference 20.1; 1.8 (1.1–2.8) 23.6; 2.2 (1.3–3.6)
Category Fluency 5.0; 0.4 (0.1–1.1) 12.5; Reference 15.2; 1.3 (0.8–2.0) 16.6; 1.4 (0.8–2.4)
Buschke Selective Reminding Test
Immediate Recall 18.8; 1.1 (0.6–2.1) 17.0; Reference 22.1; 1.4 (0.9–2.1) 22.3; 1.4 (0.9–2.3)

































Figure 1. The likelihood of cognitive impairment (adjusted odds
ratios and 95% confidence intervals) across estimated glomerular
filtration rate (eGFR) category (reference group is 45–59 mL/min
per 1.73 m2). Models were adjusted for age, sex, race, education,
diabetes, hypertension, body mass index, and depression. P-value
for trend test o.05. Modified Mini-Mental State Examination
(3MS) scores range from 0 to 100; Trail Making Test Parts A and B
(Trails A and B) scores range from 0 to 300; Boston Naming scores
range from 0 to 15; Category Fluency scores range from 0 to 45;
Buschke Immediate and Delayed Recall scores range from 0 to 12;
higher scores indicate higher function for all tests except for Trails
A and B in which lower scores are better.
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cognitive function was independent of demographics and
comorbidities.
Some limitations of the study deserve mention. As a
cross-sectional analysis, the ability to draw causal conclu-
sions between level of eGFR and cognitive function is lim-
ited. The pattern of cognitive deficits is more suggestive of
subcortical vascular disease involvement than underlying
AD, but without structural brain imaging results, the eti-
ology of clinically significant cognitive impairment cannot
be determined. Despite the large, diverse sample of patients
with CKD, these results may not be fully generalizable to
the broader population with CKD in the United States, and
CRIC participants with an eGFR of 60 mL/min per 1.73 m2
or greater most certainly are not reflective of people with
better kidney function, because they at one time had an
eGFR less than 60 mL/min per 1.73 m2. Finally, although
the effect sizes may seem small for some of the cognitive
tests (e.g., 3MS), similar effect sizes have been found in
studies investigating better-studied risk factors for cognitive
impairment, such as hypertension or dyslipidemia.34,35
In summary, this study found that lower levels of eGFR
were independently associated with impaired cognitive
functioning across multiple different domains, especially
related to tests of executive function, even after adjustment
for sociodemographic and clinical factors. These results
suggest that screening older patients with advanced CKD
for cognitive impairment might be important, but future
research is needed to determine the appropriate screening
tools and the sensitivity and specificity of various cut-points
for screening. It is hoped that the ongoing longitudinal as-
sessments of the CRIC COG Study will facilitate better un-
derstanding of the clinical importance, etiology, and
mechanisms explaining the association between CKD
severity and cognition.
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